DR. ANDREA RUDOMIN CONANT LORIO D.O.
Prescription History 1992016133
Internal Medicine - Pulmonary Disease in Houma, LA

NPI Status: Active since June 22, 2010

Contact Information

8120 MAIN STREET
SUITE 204
HOUMA, LA
ZIP 70360
Phone: (985) 850-6090
Fax: (985) 850-6099

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ANDREA RUDOMIN CONANT LORIO D.O., an active Pulmonary Disease specialist practicing in Houma, LA. Our medical registry currently tracks 15 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 565 documented patient claims. Among these therapy options, the most frequently utilized medication is Trelegy Ellipta, which accounts for 105 claims alone.


Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 87
30-Day Fills 101.5
Days Supply 2,604
LA State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills73.4
Peer Average Days Supply1,841
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 45.0% more claims than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,972.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.67

State Avg Cost Per Claim

$45.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 66
30-Day Fills 68.0
Days Supply 2,040
LA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills33.3
Peer Average Days Supply998
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 135.7% higher than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33,890.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$513.49

State Avg Cost Per Claim

$562.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Azelastine Hcl

Generic Formulation: Azelastine HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 22
30-Day Fills 39.0
Days Supply 1,170
LA State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills62.2
Peer Average Days Supply1,818
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $781.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.51

State Avg Cost Per Claim

$39.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by allergies or other conditions. Azelastine belongs to a class of drugs known as antihistamines. It works by blocking certain natural substances called histamines that are responsible for nasal symptoms.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 32
30-Day Fills 32.0
Days Supply 960
LA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills42.1
Peer Average Days Supply1,261
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,556.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$423.63

State Avg Cost Per Claim

$513.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 45
30-Day Fills 45.1
Days Supply 1,354
LA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills43.0
Peer Average Days Supply1,287
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,289.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$673.11

State Avg Cost Per Claim

$755.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Budesonide

Generic Formulation: BudesonideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 615
LA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.4
Peer Average Days Supply458
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,308.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$468.57

State Avg Cost Per Claim

$195.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.

Therapeutic Applications

Budesonide is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. This medication belongs to a class of drugs known as corticosteroids. It works directly in the lungs to make breathing easier by reducing the irritation and swelling of the airways. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Combivent Respimat

Generic Formulation: Ipratropium/Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 17.3
Days Supply 518
LA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills23.3
Peer Average Days Supply676
Conservative Utilization

This provider writes prescriptions for this formulation 36.8% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,180.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$515.06

State Avg Cost Per Claim

$607.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 24
30-Day Fills 38.0
Days Supply 1,140
LA State Average Benchmarks
Peer Average Claims63.0
Peer Average 30-Day Fills106.2
Peer Average Days Supply3,170
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.9% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $271.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.31

State Avg Cost Per Claim

$13.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Ipratropium Bromide

Generic Formulation: Ipratropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 26.5
Days Supply 794
LA State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills54.5
Peer Average Days Supply1,413
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.0% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $586.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.86

State Avg Cost Per Claim

$39.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Therapeutic Applications

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Levocetirizine Dihydrochloride

Generic Formulation: Levocetirizine DihydrochlorideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 29
30-Day Fills 43.0
Days Supply 1,290
LA State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills87.9
Peer Average Days Supply2,603
Conservative Utilization

This provider writes prescriptions for this formulation 38.3% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $227.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.83

State Avg Cost Per Claim

$15.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Levocetirizine is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, and sneezing. It is also used to relieve itching and hives. It works by blocking a certain natural substance (histamine) that your body makes during an allergic reaction. Levocetirizine does not prevent hives or prevent/treat a serious allergic reaction (such as anaphylaxis). If your doctor has prescribed epinephrine to treat allergic reactions, always carry your epinephrine injector with you. Do not use levocetirizine in place of your epinephrine.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 21.0
Days Supply 630
LA State Average Benchmarks
Peer Average Claims72.0
Peer Average 30-Day Fills144.4
Peer Average Days Supply4,292
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.2% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $112.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.47

State Avg Cost Per Claim

$12.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 60
30-Day Fills 77.6
Days Supply 1,783
LA State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills59.3
Peer Average Days Supply954
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $365.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.09

State Avg Cost Per Claim

$4.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 510
LA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills35.3
Peer Average Days Supply1,055
Conservative Utilization

This provider writes prescriptions for this formulation 37.0% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,231.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$543.06

State Avg Cost Per Claim

$653.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 21.0
Days Supply 630
LA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills43.1
Peer Average Days Supply1,290
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.1% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,293.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$552.91

State Avg Cost Per Claim

$632.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 105
30-Day Fills 125.0
Days Supply 3,734
LA State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills70.5
Peer Average Days Supply2,113
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 87.5% higher than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $84,097.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$800.93

State Avg Cost Per Claim

$820.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ANDREA RUDOMIN CONANT LORIO D.O. provides transparency into local medical care patterns within Houma, LA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.